Waterdrop Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $366.5M
- Price
- $1.02
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.97%
- Volume
- 199.1K
About
Waterdrop Inc., through its subsidiaries, provides online insurance brokerage services to match and connect users with related insurance products underwritten by insurance companies in the People’s Republic of China. The company offers short-term and long-term health and life insurance products and services. It also operates a medical crowdfunding platform; and E-Find, a clinical trial patient recruitment platform for pharmaceutical companies to find matches for clinical trials. In addition, the company provides technical services to insurance brokerage or agency companies through customer relationship management system. Waterdrop Inc. was founded in 2016 and is headquartered in Beijing, the People’s Republic of China.
Quick stats
Shares outstanding359.3M
Computed float359.3M
Float / shares100.0%
Key info
SectorFinancial Services
IndustryInsurance - Brokers
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001823986
AI Summary
AI-generated1/10
majorbullishearnings
Waterdrop Inc. Reports Second Quarter 2026 Unaudited Financial Results
Waterdrop posted Q2 2026 operating revenue of RMB1,448.2 million, up 72.8% year-over-year, with net profit attributable to ordinary shareholders of RMB125.8 million — its 18th consecutive profitable quarter.
The insurance business drove the quarter: insurance-related revenue rose 80.5% YoY and insurance operating profit reached RMB183.6 million, up 20% QoQ. The company launched Rongyibao, the market's first no-health-disclosure long-term critical illness product, and expanded the Jixing Gaozhao lifetime specified disease line.
The E-Find clinical trial platform generated RMB35.2 million in net revenue, up 26.8% YoY, now working with 255 pharma companies and CROs and having delivered 1,873 cumulative trial projects. The medical crowdfunding platform has cumulatively moved RMB74.7 billion to 3.82 million patients from roughly 499 million donors.
As of August 31, 2026, Waterdrop had repurchased approximately 62.9 million ADSs, and founder-CEO Shen Peng framed AI as the core driver for capturing growing demand across its platforms.
Red flags
- net margin remains thin at roughly 8.7% (RMB125.8M profit on RMB1,448.2M revenue) despite 72.8% revenue growth
- ADS buyback disclosed only as a cumulative figure with no authorization size or timeframe in this release
- results are unaudited; no consensus comparison provided to benchmark the growth